Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07126704Phase 1Not Yet Recruiting

A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects

Role: lead

NCT05761223Phase 1Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Role: lead

NCT05995782Phase 1Recruiting

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Role: lead

NCT04165837Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Oral FB-101 in Healthy Subjects

Role: lead

All 4 trials loaded